SCHEMBL9982148

SCHEMBL9982148

CS(=O)(=O)N1CCCN(c2ccc(N3CCN(C(=O)O)c4ccccc43)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.49
MAPT P10636 5/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 6/20 0.47
POLB P06746 3/20 0.47
TSHR P16473 1/20 0.44
MAPK10 P53779 1/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPK1 P28482 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
CYP2C9 P11712 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL975783 0.95 HSD11B1 (0.59) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3663624 0.85 KMT2A (0.49) HSD11B1MAPTMEN1KMT2AALDH1A1
SCHEMBL3718470 0.83 HSD11B1 (0.49) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL9982524 0.83 NAMPT (0.50) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL9982702 0.83 HSD11B1 (0.49) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3663979 0.82 HSD11B1 (0.51) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL9982741 0.82 HSD11B1 (0.48) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3665830 0.81 HSD11B1 (0.54) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3664472 0.81 HSD11B1 (0.63) HSD11B1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3666370 0.81 HSD11B1 (0.62) HSD11B1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238126-B1 DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2014-11-05 EP claimed
US-8211892-B2 Tetrahydroquinoxaline urea derivatives SANOFI-AVENTIS (FR) 2012-07-03 US claimed
EP-2238126-B1 DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed
US-8530657-B2 Substituted adamantanes and their therapeutic application SANOFI (FR) 2013-09-10 US disclosed
US-20120245148-A1 TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-09-27 US disclosed
US-8211892-B2 Tetrahydroquinoxaline urea derivatives SANOFI-AVENTIS (FR) 2012-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245148-A1 TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION UGDH, HNMT, NNMT HSD11B1 2913/4885SMN1; SMN2 2396/4885MAPT 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.